Tonight on Amanpour and Company, Thursday, June 4th, 2026
REPORT: INSIDE HEZBOLLAH
Just hours after Israel and Lebanon agreed to a U.S.-brokered ceasefire, the leaders of Hezbollah are rejecting the deal. The terms included a complete cessation of Hezbollah military action and the removal of its operatives from southern Lebanon. But the Iran-backed militant group insists any truce must also require an end to Israel's offensive and the withdrawal of Israeli forces. It's the fourth ceasefire announcement in just seven weeks, as the U.S. seeks to clear a major hurdle on the path to a broader agreement to end the war with Iran. For more than four decades Hezbollah has faced repeated attempts to weaken its power, yet it remains a potent force in the region. Correspondent Isobel Yeung reports from Lebanon.
Isobel Yeung
Correspondent
With no ceasefire in sight, it's ordinary Lebanese citizens that are suffering the most. Isobel Yeung joins the show from London to discuss whether anything can break Hezbollah's grip on power.
Jasmine Garsd
Immigration Correspondent, NPR
and
Aaron Reichlin-Melnick
Senior Fellow, American Immigration Council
Held without due process, fed maggot-infested meals, denied access to medical care, and given no indication of when they will be free. According to many of the 60,000 people currently held in immigration detention centers across America, this is the reality of their daily life. It's why hundreds of detainees at Delaney Hall detention center in New Jersey have reportedly been on hunger strike. Protests outside the facility escalated into clashes, with ICE officers using tear gas against demonstrators refusing to disperse. Now Senate Republicans are pushing ahead with a package that would provide billions in new funding for immigration enforcement. NPR immigration correspondent Jasmine Garsd joins the show alongside Aaron Reichlin-Melnick, a senior fellow at the American Immigration Council.
Dr. Mark Goldsmith
CEO, Revolution Medicines
A medical breakthrough is doubling the survival time for patients with one of the most aggressive forms of cancer. A new pill taken daily to treat pancreatic cancer has shown positive results in a study with 500 patients. Scientists found the drug reduced the risk of death by 60% compared with chemotherapy. Dr. Mark Goldsmith, CEO of the biotech company that funded the study, joins Hari Sreenivasan to discuss this landmark treatment.
Tonight on Amanpour and Company Airs weekdays at PBS. Check local listings.
Official Website
https://www.pbs.org/wnet/amanpour-and-company/
YT Channel link
https://www.youtube.com/@AmanpourandCompany
❤️pants